Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown
Published: April 12, 2025
Language: Английский
Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown
Published: April 12, 2025
Language: Английский
Inflammopharmacology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 27, 2025
Language: Английский
Citations
0International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 3050 - 3050
Published: March 26, 2025
Coronary microvascular dysfunction (CMD) is a key contributor to myocardial ischemia and adverse cardiovascular outcomes, particularly in individuals with metabolic disorders such as type 2 diabetes (T2D). While conventional therapies primarily target epicardial coronary disease, effective treatments for CMD remain limited. Glucagon-like peptide-1 receptor (GLP-1R) agonists have emerged promising agents benefits extending beyond glycemic control. Preclinical clinical evidence suggests that GLP-1R activation enhances function through mechanisms including improved endothelial function, increased nitric oxide bioavailability, attenuation of oxidative stress, reduced vascular inflammation. Moreover, been shown improve blood flow, perfusion reserve, high-risk populations. Despite these findings, inconsistencies across studies due variability patient populations, study designs, imaging methodologies. This review summarizes current on the role perfusion, bridging mechanistic insights outcomes. Further large-scale, well-designed trials are needed clarify their long-term impact microcirculation explore potential targeted CMD.
Language: Английский
Citations
0European Journal of Pharmacology, Journal Year: 2025, Volume and Issue: unknown, P. 177615 - 177615
Published: April 1, 2025
Language: Английский
Citations
0Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown
Published: April 12, 2025
Language: Английский
Citations
0